ArticleNano-micro letters2020
Deep-Tissue Photothermal Therapy Using Laser Illumination at NIR-IIa Window.
Article in Nano-micro letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Comparison Between Ultrasonic and Thermal Exfoliation for Molybdenum Disulfide Nanoparticles-A Multifunctional Study.Nanomaterials (Basel, Switzerland) · 2026Article
- In Vitro Evaluation of Silica-Coated BiACS omega · 2026Article
- Numerical optimization of laser radius ratio and power in photothermal therapy of various ellipsoidal tumor shape.Discover nano · 2026Article
- Resonance Energy Transfer-Driven Photothermal Nanoagent Enables Melanoma Ablation Under Low-Power Near-Infrared Irradiation.Advanced functional materials · 2026Article
- Light-Activated Iron Oxide Nanoparticles in Cancer Treatment: Synergistic Roles in Photothermal and Photodynamic Therapy.Cancers · 2026Review
- Enhanced Spin-Engineering Photothermoelectric-Enzymatic Catalysis System via Lattice Mismatch-Induced Jahn-Teller Distortion for Tumor Therapy.Nano-micro letters · 2026Article
- Engineered MoSNanomaterials (Basel, Switzerland) · 2026Review
- Dual-responsive PDA-HP hydrogel enables mitochondria-targeted mild photothermal therapy for spinal cord repair.Materials today. Bio · 2026Article
- Adaptive optical waveguide system for large-area and overheating-preventing phototherapy in deep tissue.Nature communications · 2026Article
- Engineering Dual-Loaded PLGA Nanoparticles with Gold Nanorods and Doxorubicin as Robust Multimodal Nanoplatforms.ACS omega · 2026Article
- Targeting Triple-Negative Breast Cancer: A Special Focus on Phototherapy and Nanomaterials.Molecules (Basel, Switzerland) · 2026Review
- Nanosystem-Mediated Phototherapy (PDT/PTT) - Chemodynamic Therapy for Synergistic Antitumor Therapy: Strategies and Advances.International journal of nanomedicine · 2026Review
- Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.Theranostics · 2026Review
- Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy.Materials today. Bio · 2025Review
- Avenues for integrating photothermal therapy in cancer clinic.Communications chemistry · 2025Review
- 3D-Printed Polysaccharide Scaffolds with NIR-Triggered Activity for Diabetic Wound Healing.ACS omega · 2025Article
- Advances in Second Near-Infrared Window Photothermal Agents and Photothermal Therapy for Tumors in Interdisciplinary Medical Research.Pharmaceutics · 2025Review
- A comprehensive modeling on thermal damage in tumor hyperthermia therapies using magneto-plasmonic nanocomposite.Scientific reports · 2025Article
- Multifunctional nanozymes based on MoS₂ for synergistic catalytic activity and cancer photothermal therapy.Nanomedicine (London, England) · 2025Review
- Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photothermal therapy (PTT) using near-infrared (NIR) light for tumor treatment has triggered extensive attentions because of its advantages of noninvasion and convenience. The current research on PTT usually uses lasers in the first NIR window (NIR-I; 700-900 nm) as irradiation source. However, the second NIR window (NIR-II; 1000-1700 nm) especially NIR-IIa window (1300-1400 nm) is considered much more promising in diagnosis and treatment as its superiority in penetration depth and maximum permissible exposure over NIR-I window. Hereby, we propose the use of laser excitation at 1275 nm, which is approved by Food and Drug Administration for physical therapy, as an attractive technique for PTT to balance of tissue absorption and scattering with water absorption. Specifically, CuS-PEG nanoparticles with similar absorption values at 1275 and 808 nm, a conventional NIR-I window for PTT, were synthesized as PTT agents and a comparison platform, to explore the potential of 1275 and 808 nm lasers for PTT, especially in deep-tissue settings. The results showed that 1275 nm laser was practicable in PTT. It exhibited much more desirable outcomes in cell ablation in vitro and deep-tissue antitumor capabilities in vivo compared to that of 808 nm laser. NIR-IIa laser illumination is superior to NIR-I laser for deep-tissue PTT, and shows high potential to improve the PTT outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.